Chukkapalli, V., Gordon, L. I., Venugopal, P., Borgia, J. A., & Karmali, R. (2018). Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells. Oncotarget.

Chukkapalli, Vineela, Leo I. Gordon, Parameswaran Venugopal, Jeffrey A. Borgia, and Reem Karmali. "Metabolic Changes Associated With Metformin Potentiates Bcl-2 Inhibitor, Venetoclax, and CDK9 Inhibitor, BAY1143572 and Reduces Viability of Lymphoma Cells." Oncotarget 2018.

Chukkapalli, Vineela, et al. "Metabolic Changes Associated With Metformin Potentiates Bcl-2 Inhibitor, Venetoclax, and CDK9 Inhibitor, BAY1143572 and Reduces Viability of Lymphoma Cells." Oncotarget 2018.